Pegylated interferon in the treatment of chronic delta hepatitis: the experience from real-world clinical practice ; Пегилированный интерферон в терапии хронического гепатита дельта – опыт реальной клинической практики

Συγγραφείς: Magomedova S.A., Bilalova S.K., Peradze K.D., Isaeva O.V., Kichatova V.S., Malinnikova E.Y., Ilchenko L.Y., Kyuregyan K.K., Akimkin V.G., Mikhailov M.I.

Συνεισφορές: 1

Πηγή: Almanac of Clinical Medicine; Vol 51, No 4 (2023); 227-235 ; Альманах клинической медицины; Vol 51, No 4 (2023); 227-235 ; 2587-9294 ; 2072-0505

Θεματικοί όροι: hepatitis delta, pegylated interferon alpha, virological response, biochemical response, safety, гепатит дельта, пегилированный интерферон альфа, вирусологический ответ, биохимический ответ, безопасность

Περιγραφή αρχείου: application/pdf

Relation: https://almclinmed.ru/jour/article/view/15280/1588; https://almclinmed.ru/jour/article/view/15280/1592; https://almclinmed.ru/jour/article/downloadSuppFile/15280/132996; https://almclinmed.ru/jour/article/downloadSuppFile/15280/152315; https://almclinmed.ru/jour/article/downloadSuppFile/15280/152316; https://almclinmed.ru/jour/article/downloadSuppFile/15280/152317; https://almclinmed.ru/jour/article/downloadSuppFile/15280/152318; https://almclinmed.ru/jour/article/downloadSuppFile/15280/152319; https://almclinmed.ru/jour/article/downloadSuppFile/15280/152320; https://almclinmed.ru/jour/article/view/15280

Διαθεσιμότητα: https://almclinmed.ru/jour/article/view/15280
https://doi.org/10.18786/2072-0505-2023-51-027

Efficacy and safety of the new drug against multiple sclerosis «PEGylated Interferon beta-1a Human» in monkeys compared with unmodified interferon beta-1a

Συγγραφείς: N. A. Spirina, Ja. Ju. Ustjugov, A. A. Aleksandrov, M. V. Artjuhova, A. B. Dzhelija

Πηγή: Биопрепараты: Профилактика, диагностика, лечение, Vol 16, Iss 2, Pp 108-114 (2018)

Θεματικοί όροι: интерферон бета-1а, пегилированный интерферон бета-1а, рассеянный склероз, фармакодинамика, безопасность, эффективность, токсичность, interferon beta-1a, pegylated interferon beta-1a, multiple sclerosis, pharmacodynamics, safety, efficiency, toxicity, Biotechnology, TP248.13-248.65, Medicine

Περιγραφή αρχείου: electronic resource

Relation: https://www.biopreparations.ru/jour/article/view/50; https://doaj.org/toc/2221-996X; https://doaj.org/toc/2619-1156

Σύνδεσμος πρόσβασης: https://doaj.org/article/1ae2ae23102640b6946b9378509662cb

Some safety aspects of a new russian pegylated interferon-A medication “ALGERON” (phase 1 clinical trial) ; Некоторые аспекты безопасности нового отечественного препарата пегилированного интерферона альфа 'АЛЬГЕРОН' (результаты клинического исследования I фазы)

Συγγραφείς: Тукач А.И., Фитилев С.Б., Шкребнева И.И., Возжаев А.В., Якушев В.А., Иванов Р.А., Линькова Ю.Н., Черновская Т.В.

Πηγή: Вестник Российского университета дружбы народов. Серия: Медицина

Θεματικοί όροι: пегилированный интерферон альфа, цепэгинтерферон альфа-2b, переносимость, побочные реакции, hepatitis C, maximum tolerated dose, pegylated interferon-a, Cepeginterferon alfa–2b, safety profile, step by step dose escalation

Relation: https://openrepository.ru/article?id=250523

Διαθεσιμότητα: https://openrepository.ru/article?id=250523

Some safety aspects of a new russian pegylated interferon-A medication 'ALGERON' (phase 1 clinical trial)

Πηγή: Вестник Российского университета дружбы народов. Серия: Медицина

Θεματικοί όροι: пегилированный интерферон альфа, maximum tolerated dose, переносимость, pegylated interferon-a, цепэгинтерферон альфа-2b, побочные реакции, hepatitis C, safety profile, step by step dose escalation, Cepeginterferon alfa–2b

Σύνδεσμος πρόσβασης: https://openrepository.ru/article?id=250523

Истинная полицитемия у больных дет- ского и подросткового возраста (анализ семи случаев)

Θεματικοί όροι: polycythemia vera, treatment, children, diagnostics, диагностика, руксолитиниб, pegylated interferon, пегилированный интерферон, лечение, дети, истинная полицитемия, 3. Good health

Σύνδεσμος πρόσβασης: https://www.htjournal.ru/jour/article/view/114/110
https://www.htjournal.ru/jour/article/download/114/110
https://cyberleninka.ru/article/n/istinnaya-politsitemiya-u-bolnyh-detskogo-i-podrostkovogo-vozrasta-analiz-semi-sluchaev

Success of early antiviral monotherapy with pegylated interferon α-2a for posttransplantation fibrosing cholestatic hepatitis C (a clinical case) ; Успех ранней противовирусной монотерапии пегилированным интерфероном альфа-2а посттрансплантационного фиброзирующего холестатического гепатита С (клиническое наблюдение)

Συγγραφείς: A. V. Chzhao, O. I. Andreitseva, V. E. Syutkin, A. O. Chugunov, K. R. Dzhagrayev, A. A. Saliyenko, I. V. Aleksandrova, V. V. Artamonov, E. A. Soldatov, L. V. Donova, I. E. Galankina, L. N. Zimina, А. В. Чжао, О. И. Андрейцева, В. Е. Сюткин, А. О. Чугунов, К. Р. Джаграев, А. А. Салиенко, И. В. Александрова, В. В. Артамонов, Е. А. Солдатов, Л. В. Донова, И. Е. Галанкина, Л. Н. Зимина

Πηγή: Transplantologiya. The Russian Journal of Transplantation; № 2-3 (2011); 69-74 ; Трансплантология; № 2-3 (2011); 69-74 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2011-0-2-3

Θεματικοί όροι: пегилированный интерферон альфа-2а, posttransplantation fibrosing cholestatic hepatitis, antiviral therapy, pegylated interferon α-2a, посттрансплантационный фиброзирующий холестатический гепатит, противовирусная терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.jtransplantologiya.ru/jour/article/view/339/400; Terrault N.A., Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver transplant 2006;12(8):1192–204.; Сюткин В.Е., Андрейцева О.И., Чжао А.В. Дисфункция трансплантата печени, обусловленная инфекцией гепатита С. Трансплантология 2010; (3–4): 37–45.; Haque M., Hashim A., Greanya E.D. et al. Spontaneous clearance of hepatitis C infection post-liver transplant: A rare but real phenomenon? A case report and review of the literature. Annals of hepatology 2010;9(2):202–6.; Narang T.K., Ahrens W., Russo M.W. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2010;16(11):1228–35.; Davies S.E., Portmann B.C., Grady J.G. et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13(1):150–7.; Adeyi O., Fischer S.E., Guindi M. Liver allograft pathology: approach to interpretation of needle biopsies with clinicopathological correlation. J Clin Pathology 2010;63(1):47–74.; Wiesner R.H., Sorrell M., Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver transpl 2003;9(11):1–9.; Honda M., Kaneko S., Matsushita E. et al. Cell cycle regulation of hepatitis C virus internal ribosomal entry sitedirected translation. Gastroenterology 2000;118(1):152–62.; Zekry A., Bishop G.A., Bowen D.G. et al. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 2002;8(3):292–301.; https://www.jtransplantologiya.ru/jour/article/view/339

Διαθεσιμότητα: https://www.jtransplantologiya.ru/jour/article/view/339
https://doi.org/10.23873/2074-0506-2011-0-2-3-69-74

Treatment for recurrent HCV infection after liver transplantation for final stages of chronic hepatitis С ; Лечение возвратной инфекции HCV после трансплантации печени по поводу терминальных стадий хронического гепатита С

Συγγραφείς: V. E. Syutkin, O. I. Andreitseva, A. V. Kozlova, В. Е. Сюткин, О. И. Андрейцева, А. В. Козлова

Πηγή: Transplantologiya. The Russian Journal of Transplantation; № 2 (2010); 10-17 ; Трансплантология; № 2 (2010); 10-17 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2010-0-2

Θεματικοί όροι: трансплантация печени, pegylated interferon, ribavirin, cyclosporine, liver transplantation, пегилированный интерферон, рибавирин, циклоспорин

Περιγραφή αρχείου: application/pdf

Relation: https://www.jtransplantologiya.ru/jour/article/view/277/340; Terrault N.A., Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006;12:1192–204.; Gish R.G., Afdhal N.H., Dieterich D.T., Reddy K.R. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005;3:311–8.; Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17–35.; Berenguer M., Prieto M., Rayon J.M. et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852–8.; Berenguer M., Palau A., Fernandez A. et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12:1067–76.; Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002;8 (suppl 1):14–8.; Thuluvath P.J., Krok K.L., Segev D.L. et al. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007;13:719–24.; Saab S., Niho H., Comulada S. et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver Int 2005;25:940–5.; Sheiner P.A., Boros P., Klion F.M. et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831–8.; Singh N., Gayowski T., Wannstedt C.F. et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 1998;65:82–6.; Belli L.S., Alberti A.B., Rondinara G.F. et al. Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus positive liver transplant recipients: interim report of a prospective randomized trial. Transplant Proc 2001;33:1353–4.; Mazzaferro V., Tagger A., Schiavo M. et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001;33:1355–7.; Sugawara Y., Makuuchi M., Matsui Y. et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78:1308–11.; Shergill A.K., Khalili M., Straley S. et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005;5:118–24.; Chalasani N., Manzarbeitia C., Ferenci P. et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trial (published erratum appears in Hepatology 2005;42:506). Hepatology 2005; 41:289–98.; Castells L., Vargas V., Allende H. et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43:53–9.; Zimmermann T., Bocher W.O., Biesterfeld S. et al. Efficacy of an escalating dose regimen of pegylated interferon alpha2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007; 20:583–90.; Kuo A., Tan V., Lan B. et al. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl 2008;14:1491–7.; Wang C.S., Ko H.H., Yoshida E.M. et al. Interferon-based combination antiviral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006;6:1586–99.; Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274–87.; Bizollon T., Pradat P., Mabrut J.Y. et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007;7:448–53.; Nair S., Lipscomb J., Eason J. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. Transplantation 2008;86:418–22.; Ueda Y., Takada Y., Haga H. et al. Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation. Transplantation 2009;85:855–62.; Raziorrouh B., Jung M.C., Schirren C.A. et al. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12. Eur J Gastroenterol Hepatol 2008;20:778–83.; Dinges S., Morard I., Heim M. et al. Pegylated interferon alpha 2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. Transpl Infect Dis 2009;11:33–9.; Walter T., Scoazec J.Y., Guillaud O. et al. Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact. Liver Transpl 2009; 15:54–63.; Cescon M., Grazi G.L., Cucchetti A. et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009;15:782–9.; Berenguer M., Aguilera V., Prieto M. et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009;15:738–46.; Jain A., Sharma R., Ryan C. et al. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clin Transplant 2010;24:104–11.; Torriani F.J., Ribeiro R.M., Gilbert T.L. et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003;188:1498–507.; Adeyemi O.M. Hepatitis C in HIVpositive patients – treatment and liver disease outcomes. J Clin Gastroenterol 2007;41:75–87.; Oton E., Barcena R., Moreno-Planas J.M. et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006;6:2348–55.; Dumortier J., Scoazec J.Y., Chevallier P. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669–74.; Bahra M., Neumann U.P., Jacob D. et al. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007;83: 351–3.; Bizollon T., Pradat P., Mabrut J.Y. et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005;5:1909–13.; Picciotto F.P., Tritto G., Lanza A.G. et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459–65.; Lilly L., Selzner N., Therapondos G. et al. Improved survival in liver transplant recipients (LT) treated for recurrent hepatitis C (HCV) is seen in both relapsers and in sustained responders. Paper presented at: 2008 American Transplant Congress; May 31–June 4, 2008. Toronto, Canada.; Ikegami T., Taketomi A., Soejima Y. et al. The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C. Transplant Proc 2009;41(10):4246–52.; Veldt B.J., Poterucha J.J., Watt K.D.S. et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transpl 2008;8:2426–33.; Fernandez I., Meneu J.C., Colina F. et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006;12:1805–12.; Sharma P., Marrero J.A., Fontana R.J. et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007;13:1100–8.; Carrion J.A., Navasa M., GarcıґaRetortillo M. et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746–56.; Hanouneh I.A., Miller C., Aucejo F. et al. Recurrent hepatitis C after liver transplantation: on treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008;14:53–8.; Donato M., Agnelli F., Rigamonti C. et al. Might rapid virological response be used as a stopping rule in liver transplant recipients treated with pegylated interferon plus ribavirin? Liver Transpl 2008;14:1383–4.; Samuel D., Bizollon T., Feray C. et al. Interferon-α2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642–50.; Сюткин В.Е. Новые возможности повышения эффективности противовирусной терапии больных хроническим гепатитом С. Инфекц бол 2009;7(2):55–9.; Schmidt S.C., Bahra M., Bayraktar S. et al. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci. 2009 Oct 2. [Epub ahead of print].; Moeller M., Divine G., Brown K.A. Impact of length of therapy and predictive value models on SVR in HCV patients post OLT. Hepatology 2009;50:391.; Angelico M., Petrolati A., Lionetti R. et al. A randomized study on Peginterferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007;46:1009–17.; Vollmer J., Rankin R., Hartmann H. et al. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother 2004; 48:2314–17.; Zhang Y., Jamaluddin M., Wang S. et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003;77:5933–47.; Dixit N.M., Layden J., Layden T. et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004;432:922–4.; Calmus Y., Duvoux C., Pageaux G.P. et al. Multicenter randomized trial in HCV infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation: final report. Paper presented at: 2008 American Transplant Congress; May 31–June 4, 2008. Toronto, Canada.; Lionetti R., Tisone G., Palmieri G. et al. Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression. Dig Liver Dis 2010;42(4):297–303.; Brok J., Gluud L.L., Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane hepato-biliary group systematic review and meta-analysis of randomized trial. Am J Gastroenterol 2006;101(4):842–7.; Stravitz R.T., Shiffman M.L., Sanyal A.J. et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. LiverTranspl 2004;10:850–8.; Giostra E., Kullak-Ublick G.A., Keller W. et al. Ribavirin/interferon alpha sequential treatment of recurrent hepatitis C after liver transplantation.Transpl Int 2004;17:169–76.; Jolley W.B., Call T.W., Alvord L.S., Hinshaw D.B. Immunosuppressive activity of ribavirin using the rabbit skin allograft model. Ann NY Acad Sci 1977;284:230–2.; Kontorinis N., Agarwal K., Elhajj N. et al. Pegylated interferon induced immunemediated hepatitis post-liver transplantation. LiverTranspl 2006; 12:827–30.; Watashi K., Hijakata M., Hosaka M. et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282–8.; Nakagawa M., Sakamoto N., Enomoto N. et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004;313:42–7.; Manire T., Ethier C., Raymond V.A. et al. Evaluation of the effect of immunosuppressive agents on hepatitis C: cyclosporine reduces viral replication in the replicon model [abstract]. Transplantation 2004;78 (suppl 1):13–4.; Sheiner P.A., Schwartz M.E., Mor E. et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30–4.; Johnson M.W., Washburn W.K., Freeman R.B. et al. Hepatitis C viral infection in liver transplantation. Arch Surg 1996;131:284–91.; Paik S.W., Tan H.P., Klein A.S. et al. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci 2002;47:450–5.; Duvoux C., Mennecier D., Pageaux G. et al. Immunosuppression with tacrolimus an absence of antihypertensive therapy are associated with fibrosis progression after hepatitis C virus (HCV) graft reinfection. International Society of Transplantation Congress 2002 [abstract 2652]. Transplantation 2002;74(Suppl).; Hunt J., Gordon F.D., Lewis W.D. et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens. Liver Transpl 2001;7:1056–63.; Berenguer M., Prieto M., San Juan F. et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202–10.; Ghobrial R.M., Farmer D.G., Baquerizo A. et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation duringan 8-yearsinglecenterexperience. Ann Surg 1999;6:824–33.; Neumann U.P., Berg T., Bahra M. et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226–31.; Levy G., Grazi G.L., Sanjuan F. et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006;12:1464–72.; Firpi R.J., Zhu H., Morelli G. et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006;12:51–7.; Selzner N., Renner E.L., Selzner M. et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009;88(10):1214–21.; https://www.jtransplantologiya.ru/jour/article/view/277

Διαθεσιμότητα: https://www.jtransplantologiya.ru/jour/article/view/277
https://doi.org/10.23873/2074-0506-2010-0-2-10-17

EFFICACY AND SAFETY OF THE COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON ALFA-2A IN PATIENTS WITH CHRONIC HEPATITIS C: THE RESULTS OF TWO MULTICENTER, PROSPECTIVE, OPEN, NON-COMPARATIVE CLINICAL TRIALS ; ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ КОМБИНАЦИИ РИБАВИРИНА И ПЕГИЛИРОВАННОГО ИНТЕРФЕРОНА АЛЬФА-2А У ПАЦИЕНТОВ С ХРОНИЧЕСКИМ ГЕПАТИТОМ С: РЕЗУЛЬТАТЫ ДВУХ МУЛЬТИЦЕНТРОВЫХ, ПРОСПЕКТИВНЫХ, ОТКРЫТЫХ, НЕСРАВНИТЕЛЬНЫХ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ

Συγγραφείς: K. V. Zhdanov, I. G. Bakulin, D. A. Gusev, V. G. Morozov, K. V. Kozlov, К. В. Жданов, И. Г. Бакулин, Д. А. Гусев, В. Г. Морозов, К. В. Козлов

Πηγή: Journal Infectology; Том 9, № 4 (2017); 59-68 ; Журнал инфектологии; Том 9, № 4 (2017); 59-68 ; 2072-6732 ; 10.22625/2072-6732-2017-9-4

Θεματικοί όροι: рибавирин, HIV infection, cirrhosis, pegylated interferon alfa-2a, ribavirin, ВИЧинфекция, цирроз, пегилированный интерферон альфа2а

Περιγραφή αρχείου: application/pdf

Relation: https://journal.niidi.ru/jofin/article/view/657/579; Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence // Hepatology. – 2013. – Vol. 57(4) – P. 1333-1342.; EASL Recommendations on Treatment of Hepatitis C 2015 // Journal of Hepatology. – 2015. – Vol. 63. – P. 199-236.; Богословская, Е.В. Оценка эффективности противовирусной терапии хронического гепатита С в максимально ранние сроки / Е.В. Богословская [и др.] // РЖГГК. – 2007. – № 2. – С. 35–39.; Бивол, С. Гепатит С в России: эпидемия бездействия. – Издание в рамках проекта «Доступность лечения гепатита С в России: оценка ситуации и выработка рекомендаций для дальнейших действий», финансируемого Фондами «Открытое общество» / С. Бивол, А. Саранг. – http://www. domjour.ru/sites/default/files/Gepatit-otchet-FAR-2013.pdf.; Официальная статистика ВИЧ, СПИДа в России (свежие данные). – Статистика. – https://spid-vich-zppp.ru/statistika/ofitsialnaya-statistika-vich-spid-rf-2016.html.; Мурыванова, Н.Н. Социальные проблемы ВИЧинфекции регионального уровня / Н.Н. Мурыванова // Фундаментальные и прикладные исследования в современном мире. Материалы IV Международной научно-практической конференции. – 2013. – С. 184–191.; Белозеров, Е.С. ВИЧ-инфекция : руководство для врачей / Е.С. Белозеров. – СПб.: ИнформМед., 2012. – 171 с.; Ющук, Н.Д. Комбинированная терапия хронического гепатита С пегилированным интерфероном α-2а и рибавирином у больных с ВИЧ-инфекцией и больных с моноинфекцией HCV / Н.Д. Ющук [и др.] // РЖГГК. – 2009. – № 1. – С. 35–42.; Ascione, M. de Luca, M. T. Tartaglione, F. Lampasi, G. G. di Costanzo, A. G. Lanza, F. P. Picciotto, G. Marino-Marsilia, L. Fontanella, G. Leandro. Комбинация пэгинтерферона альфа-2a и рибавирина более эффективна для лечения хронического вирусного гепатита C, чем комбинация пэгинтерферона альфа-2b и рибавирина // Гастроэнтерология. – 2014. – № 1 (51). – С. 69–77.; Саркисянц, Н.К. Опыт прогнозирования побочных эффектов лечения хронического вирусного гепатита С пэгинтерфероном α-2а с рибавирином / Н.К. Саркисянц, Э.Г. Григорян // Клиническая медицина. – 2013. – № 5. – С. 46–49.; Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy // Gut. – 2006. – Vol. 55. – P. 1631-1638.; Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update // Hepatology. – 2009. – Vol. 49/ – P. 1335-1374.; Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial // Lancet. – 2001. – Vol.358. – P. 958-965.; Mc Hutchison JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group // N. Engl. J. Med. – 1998. – Vol. 339. – P. 1485-1492.; Sporea I., Danila M., Sirli R. et al. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis // J. Gastrointest. Liver Dis. – 2006. – Vol.15. – P. 125-130.; Yenice N., Mehtap O., Gumrah M. et al. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients // Turk. J. Gastroenterol. – 2006. – Vol. 17. – P. 94-98.; Pockros PJ. An urgency to identify and treat chronic hepatitis C // Minerva Gastroenterol Dietol. – 2005. Vol. 51. – P. 235-246.; Ющук, Н.Д. Протокол диагностики и лечения больных вирусными гепатитами В и С / Н.Д. Ющук [и др.] // Российский журнал гастоэнтерологии, гепатологии, колопроктологии. – 2010. – №20 (6). – С. 4–60.; Weksler B. B. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease // Aliment. Pharmacol. Ther. – 2007. – Vol. 26 (1). – P. 13-19.; Huang Y., Li M.-H., Hou M., Xie Y. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals // Hepatobiliary Pancreat Dis Int. – 2017. – Vol. 16 (5). – P. 470-479.; https://journal.niidi.ru/jofin/article/view/657

Διαθεσιμότητα: https://journal.niidi.ru/jofin/article/view/657
https://doi.org/10.22625/2072-6732-2017-9-4-59-68

Efficacy and safety of the new drug against multiple sclerosis «PEGylated Interferon beta-1a Human» in monkeys compared with unmodified interferon beta-1a ; Эффективность и безопасность нового препарата для лечения рассеянного склероза «пегилированный интерферон бета-1а человека» на обезьянах в сравнении с немодифицированным интерфероном бета-1а

Συγγραφείς: N. A. Spirina, Ja. Ju. Ustjugov, A. A. Aleksandrov, M. V. Artjuhova, A. B. Dzhelija, Н. А. Спирина, Я. Ю. Устюгов, А. А. Александров, М. В. Артюхова, А. Б. Джелия

Πηγή: Biological Products. Prevention, Diagnosis, Treatment; Том 16, № 2 (2016); 108-114 ; БИОпрепараты. Профилактика, диагностика, лечение; Том 16, № 2 (2016); 108-114 ; 2619-1156 ; 2221-996X ; undefined

Θεματικοί όροι: toxicity, пегилированный интерферон бета-1а, рассеянный склероз, фармакодинамика, безопасность, эффективность, токсичность, interferon beta-1a, PEGylated interferon beta-1a, multiple sclerosis, pharmacodynamics, safety, efficiency

Περιγραφή αρχείου: application/pdf

Relation: https://www.biopreparations.ru/jour/article/view/50/99; Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing remitting multiple sclerosis: are they equally efficacious? A comparative review of open label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord. 2011; 4(5): 281-96.; Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon therapy and their management. Neurology 1999; 53: 1622-7.; ГОСТ Р 53434-2009. Принципы надлежащей лабораторной практики.; Об утверждении Правил лабораторной практики. Приказ Министерства здравоохранения и социального развития РФ № 708н от 23 августа 2010 г.; Миронов АН, ред. Руководство по проведению доклинических исследований лекарственных средств. М.: Гриф и К; 2012.; Draft consensus guideline Addendum to ICH S6 - Preclinical safety evaluation of biotechnology-derived pharmaceuticals; 2009.; ICH S6 - Preclinical safety evaluation of biotechnology-derived pharmaceuticals; 1997.; Rejdak K, Leary SM, Stelmasiak Z, et al. Urinary nitric oxide metabolites and neopterin as markers of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients. Journal of the neurological sciences 2005; 238: 244.; Bagnato F, Durastanti V, Finamore L, Volante G, Millefiorini E. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis. Neurol Sci 2003; 24: 301-4.; Matson MA, Zimmerman TR, Tuccillo D, Tang Y, Deykin A. Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment. Curr Med Res Opin. 2011; 27(12): 2271-8.; Куксова МИ. Кроветворная система обезьян в норме и патологии. М.: Медицина; 1972.; Tremlett HL, Oger J. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler. 2004; 10: 298-301.; Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006, 108: 3253-61.; https://www.biopreparations.ru/jour/article/view/50; undefined

Διαθεσιμότητα: https://www.biopreparations.ru/jour/article/view/50

Some safety aspects of a new russian pegylated interferon-A medication 'ALGERON' (phase 1 clinical trial)

Συγγραφείς: A I Tukach, S B Fitilev, I I Shkrebniova, A V Vozzhaev, V A Yakushev, R A Ivanov, Yu N Lin’kova, T V Chernovskaya

Πηγή: RUDN Journal of Medicine, Vol 0, Iss 2, Pp 114-118 (2014)

Θεματικοί όροι: пегилированный интерферон альфа, цепэгинтерферон альфа-2b, переносимость, побочные реакции, Medicine

Περιγραφή αρχείου: electronic resource

Relation: http://journals.rudn.ru/medicine/article/view/2867; https://doaj.org/toc/2313-0245; https://doaj.org/toc/2313-0261

Σύνδεσμος πρόσβασης: https://doaj.org/article/b3f82f65f8ea486bb2df1ec42ad50214

Возможность обратного развития фиброза печени, вызванного хроническим гепатитом с, под влиянием терапии пегилированным интерфероном и рибавирином ; The ability to reverse the development of liver fibrosis caused by chronic hepatitis с responding to interferon/ribavirin therapy

Συγγραφείς: Patlusov, Е. Р., Kovaleva, N. B., Pukhtinskaya, P. S., Патлусов, Е. П., Ковалева, Н. Б., Пухтинская, П. С.

Θεματικοί όροι: HEPATITIS C, LIVER FIBROSIS, SUSTAINED VIROLOGICAL RESPONSE, PEGYLATED INTERFERON, CEPEGINTERFERON ALFA, ХРОНИЧЕСКИЙ ГЕПАТИТ С, ФИБРОЗ ПЕЧЕНИ, УСТОЙЧИВЫЙ ВИРУСОЛОГИЧЕСКИЙ ОТВЕТ, ПЕГИЛИРОВАННЫЙ ИНТЕРФЕРОН, ЦЕПЭГИНТЕРФЕРОН АЛЬФА

Περιγραφή αρχείου: application/pdf

Relation: Уральский медицинский журнал. 2016. T. 144, № 11.; http://elib.usma.ru/handle/usma/13373

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/13373

THE SAFETY OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C USING PEG-INTERFERON AND RIBAVIRIN IN HIV PATIENTS RECEIVING HAART ; БЕЗОПАСНОСТЬ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ХРОНИЧЕСКОГО ГЕПАТИТА С ПЕГИЛИРОВАННЫМ ИНТЕРФЕРОНОМ И РИБАВИРИНОМ У ПАЦИЕНТОВ С ВИЧ-ИНФЕКЦИЕЙ, ПОЛУЧАЮЩИХ ВААРТ

Συγγραφείς: T. A. Stasishkis, N. V. Dunaeva, A. Yu. Kovelenov, G. N. Isaeva, Татьяна Алексеевна Стасишкис, Наталья Викторовна Дунаева, Алексей Юрьевич Ковеленов, Галина Николаевна Исаева

Πηγή: HIV Infection and Immunosuppressive Disorders; Том 7, № 2 (2015); 27-40 ; ВИЧ-инфекция и иммуносупрессии; Том 7, № 2 (2015); 27-40 ; 2077-9828 ; 10.22328/2077-9828-2015-7-2

Θεματικοί όροι: PEG-interferon, ВГС/ВИЧ-инфекция, ВААРТ, рибавирин, пегилированный интерферон, chronic viral hepatitis C, HCV/HIV co-infection, HAART, ribavirin

Περιγραφή αρχείου: application/pdf

Relation: https://hiv.bmoc-spb.ru/jour/article/view/81/82; HIV/AIDS [доступ 20 января 2015].- URL: http://www.who.int/features/qa/71/en/.; Rockstroh J.K., Mocroft A., Soriano V., Tural C., Losso M.H., Horban A., Kirk O., Phillips A., Ledergerber B., Lundgren J. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy // J Infect Dis.- 2005.- Vol. 192 (6).- R 992-1002.; Hernandez M.D., Sherman K.E. HIV/HCV co-infection natural history and disease progression, a review of the most recent literature // Curr. Opin.- HIV AIDS.- 2011.- Vol. 6(6).- R 478-482.; Lo Re III V., Kallan M.J., Tate J.P., Localio A.R., Lim J.K., Goetz M.B., Klein M.B., Rimland D., Rodriguez-Barradas M.C., Butt A.A., Gibert C.L., Brown S.T., Park L., Dubrow R., Reddy K.R., Kostman J.R., Strom B.L., Justice A.C. Hepatic decompensation in antiretroviral-treated patients co-Infected with HIV and hepatitis C virus compared with Hepatitis C virus-monoinfected patients: a cohort study // Ann Intern Med.- 2014.- Vol. 160 (6).- R 369-379.; Konerman M.A., Mehta S.H., Sutcliffe C.G., Vu T., Higgins Y., Torbenson M.S., Moore R.D., Thomas D.L., Sulkowski M.S. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs // Hepatology.- 2014.- Vol. 59 (3).- R 767-775.; Fuster D., Cheng D.M., Quinn E.K. Nunes D., Saitz R., Jeffrey H., Samet J.H., Tsui J.I. Chronic Hepatitis C Virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems // Addiction.- 2014.- Vol. 109 (1).- R 62-70.; The Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study // AIDS.- 2010.- Vol. 24 (10).- R 1537-1548.; Bani-Sadr F., Lapidus N., Bedossa P., De Boever C.M., Perronne C., Halfon P., Pol S., Carrat F., Cacoub P. Rrogression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors // Clin. Infect. Dis.- 2008.- Vol. 46(5).- R 768-774.; Casado J.L., Quereda С., Moreno А., Pérez-Elias M.J., Marti-Belda P., Moreno S. Regression of liver fibrosis is progressive after sustained viro-logical response to HCV therapy in patients with hepatitis C and HIV coinfection // J. Virall Hepat.- 2013. Vol. 20 (12).- R 829-837.; Labarga P., Fernandez-Montero J.V., Barreiro P., Pinilla J., Vispo E., de Mendoza C., Plaza Z., Soriano V. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy // J. Viral. Hepat.- 2014.- Vol. 21 (7).- R 475-479.; Akhtar E., Manne V., Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy. A meta-analysis // Liver International.- 2015. Vol. 35 (1).- R 30-36.; Berenguer J., Alvarez-Pellicer J., Martin P.M., López-Aldeguer J., Von-Wichmann M.A., Quereda C., Mallolas J., Sanz J., Tural C., Bellón J.M., González-Garcia J. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients co-infected with human immunodeficiency virus and hepatitis C virus // Hepatology.- 2009.- Vol. 50 (2).- R 407-413.; Berenguer J., Rodríguez E., Miralles P., Von Wichmann M.A., López-Aldeguer J., Mallolas J., Galindo M.J., Van Den Eynde E., Téllez M.J., Quereda C., Jou A., Sanz J., Barros C., Santos I., Pulido F., Guardiola J.M., Ortega E., Rubio R., Jusdado J.J., Montes M.L., Gaspar G., Esteban H., Bellón J.M., González-Garcia J. GESIDA HIV/HCV Cohort Study Group. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus // Clin. Infect. Dis.- 2012.- Vol. 55 (5).- R 728-736.; Van der Meer A.J., Veldt B.J., Feld J.J., Wedemeyer H., Dufour J.F., Lammert F., Duarte-Rojo A., Heathcote E.J., Manns M.P., Kuske L., Zeuzem S., Hofmann W.P., de Knegt R.J., Hansen B.E., Janssen H.L. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis // JAMA.- 2012.- Vol. 308 (24).- P 2584-2593.; EASL Clinical Practice Guidelines: Management of hepatitis C virus infection // J. Hepatology.- 2011.- Vol. 55 (2).- P 245-264.; Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., Peters M.G., Koziel M.J., Bhan A.K., Alston B., Colquhoun D., Nevin T., Harb G., van der Horst C. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons // N. Engl. J. Med.- 2004.- Vol. 351 (5).- P 451-459.; Laufer N., Laguno M., Perez I., Cifuentes C., Murillas J., Vidal F., Bonet L., Veloso S., Gatell J.M., Mallolas J. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin // Antivir. Ther.- 2008.- Vol. 13 (7).- P 953-957.; Vispo E., Barreiro P., Pineda J.A., Mira J.A., Maida I., Martin-Carbonero L., Rodríguez-Nóvoa S., Santos I., López-Cortes L.F., Merino D., Rivero A., Soriano V. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir // Antivir. Ther.- 2008.- Vol. 13 (3).- P 429-437.; Amorosa V.K., Slim J., Mounzer K., Bruno C., Hoffman-Terry M., Dorey-Stein Z., Ferrara T., Kostman J.R., Lo Re V. 3rd The influence of abacavir and other antiretroviral agents on virologic response to hepatitis C virus therapy among antiretroviral-treated HIV-infected patients // Antivir. Ther.- 2010.- Vol. 15 (1).- P 91-99.; Vogel M., Ahlenstiel G., Hintsche B., Fenske S., Trein A., Lutz T., Schürmann D., Stephan C., Khaykin P., Bickel M., Mayr C., Baumgarten A., Buggisch P., Klinker H., John C., Gölz J., Staszewski S., Rockstroh J.K. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals // Eur. J. Med. Res.- 2010.- Vol. 15 (3).- P 102-111.; Vellozzi С., Buchacz K., Baker R., Spradling P.R., Richardson J., Moorman A., Tedaldi E., Durham M., Ward J., Brooks J.T. Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007 // J. Viral. Hepat.- 2011.- Vol. 18 (5).- P 316-324.; James P.D., Wong D.K.H. Optimizing hepatitis C therapy in HIV/hepatitis C virus (HCV) coinfected patients: analysis of HCV viral kinetics on treatment // Can. J. Infect. Dis. Med. Microbiol.- 2012.- Vol. 23 (1).- P 31-35.; Davies A., Singh K.P., Shubber Z., Ducros P., Mills E.J., Cooke G., Ford N. Treatment outcomes of treatment-naïve hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts // PLoS. One.- 2013.- Vol. 8 (2).- e55373.; Ioannou G.N., Scott J.D., Yang Y., Green P.K., Beste L.A. Beste rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide Study of 619 patients // Aliment. Pharmacol. Ther.- 2013.- Vol. 38 (11-12).- P. 1373-1384.; Beisel C., Heuer M., Otto B., Jochum J., Schmiedel S., Hertling S., Degen O., Lüth S., van Lunzen J., Schulze Zur Wiesch J. German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients // AIDS Research and Therapy.- 2014.- Vol. 11.- P 16-24.; Стасишкис Т.А., Дунаева Н.В., Ковеленов А.Ю., Исаева Г.Н. Эффективность противовирусной терапии хронического гепатита С на фоне ВААРТ у ВИЧ-позитивных пациентов // Инфекционные болезни.- 2013.- Том 11 (2).- С. 13-20.; Максимов С.Л., Иванова Л.М., Кравченко А.В., Серебровская Л.В., Ольшанский А.Я., Моргунова Н.М., Ющук Н.Д. Особенности терапии хронического гепатита С пегилированным интерфероном альфа 2а и рибавирином у больных ВИЧ-инфекцией // Тер. Архив.- 2007.- Том 97 (11).- С. 40-44.; Wada М., Marusawa H., Yamada R., Nasu A., Osaki Y., Kudo M., Nabeshima M., Fukuda Y., Chiba T., Matsuda F. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients // J. Viral. Hepat.- 2009.- Vol. 16 (6).- P 388-396.; Martin-Carbonero L., Tuma P., Vispo E., Medrano J., Labarga P., Gonzalez-Lahoz J., Barreiro P., Soriano V. Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis // J. Viral Hepat.- 2011.- Vol. 18 (8).- P 542-548.; Кравченко А.В., Куимова У.А., Ганкина Н.Ю., Канестри В.Г., Чуланов В.П. Предикторы устойчивого вирусологического ответа при терапии хронического гепатита пегилированным интерфероном и рибавирином у больных ВИЧ-инфекцией // Инфекционные болезни.- 2014.- Том 12 (2).- С. 30-34.; De Franceschi L., Fattovich G., Turrini F., Ayi K., Brugnara C., Manzato F., Noventa F., Stanzial A.M., Solero P., Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage // Hepatology.- 2000.- Vol. 31 (4).- P 997-1004.; Tanaka H., Miyano M., Ueda H., Fukui K., Ichinose M. Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C // Clin. Exp. Med.- 2005.- Vol. 5.- P 190-195.; Sakamoto N., Tanaka Y., Nakagawa M., Yatsuhashi H., Nishiguchi S., Enomoto N., Azuma S., Nishimura-Sakurai Y., Kakinuma S., Nishida N., Tokunaga K., Honda M., Ito K., Mizokami M., Watanabe M. ITPA gene variant protects against anemia induced by pegylated interferon-and ribavirin therapy for Japanese pa-tients with chronic hepatitis C // Hepatology Research.- 2010.- Vol. 40 (11).- P 1063-1071.; Hitomi Y., Cirulli E.T., Fellay J., McHutchison J.G., Thompson A.J., Gumbs C.E., Shianna K.V., Urban T.J., Goldstein D.B. Inosine tripfosphate protects against ribavirin-induced ATP loss by restoring adenylosuccinate synthase function // Gastroenterology.- 2011.- 140 (4).- P 1314-1321.; Domingo P., Guardiola J.M., Salazar J., Torres F., Mateo M.G., Pacho C., Del Mar Gutierrez M., Lamarca K., Fontanet A., Martin J., Muñoz J, Vidal F., Baiget M. Association of ITPA gene polymorphisms and the risk of ribavirin-Induced anemia in HIV/Hepatitis C Virus (HCV)-coinfec-ted patients receiving HCV combination therapy // Antimicrobial Agents and Chemotherapy.- 2012.- Vol. 56 (6).- P 2987-2993.; Altintas Z.M., Altintas E., Sezgin O., Edgunlu T.G., Ucbilek E., Nayir E., Barlas I.O., Erdal M.E. The effect of genetic variations of methylene tetrahydropholate reductase gene polymorphisms on ribavirin-induced anemia in hepatitis C patients // J. Liver: Dis. Transplant.- 2013.- Vol. 2 (1).- P 1-8.; D'Avolio A., De Nicolö A., Cusato J., Ciancio A., Boglione L., Strona S., Cariti G., Troshina G., Caviglia G.P., Smedile A., Rizzetto M., Di Perri G. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients // Antiviral Res.- 2013.- Vol. 100 (1).- P 114-119.; Fujino T., Aoyagi Y., Takahashi M., Yada R., Yamamoto N., Ohishi Y., Nishiura A., Kohjima M., Yoshimoto T., Fukuizumi K., Nakashima M., Kato M., Kotoh K., Nakamuta M., Enjoji M. Association of ITPA polymorphism with outcomes of peginterferon- plus ribavirin combination therapy // World J. Gastrointest. Pharmacol. Ther.- 2013.- Vol. 4 (3).- P 54-60.; Amanzada A., Goralczyk A.D., Reinhardt L., Moriconi F., Cameron S., Mihm S. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy // BMC Infect. Dis. - 2014.- Vol. 14.- P 503 - 512.; Ganser A., Carlo-Stella C., Greher J., Völkers B., Hoelzer D. Effect of recombinant interferons alpha and gamma on human marrow-derived megakaryocytic progenitor cells // Blood.- 1987.- Vol. 70 (4).- P 1173 - 1179.; Chang C-S., Yan S-L., Lin H-Y., Yu F-L., Tsai C-Y. Pure red cell aplasia caused by pegylated interferon- -2a plus ribavirin in the treatment of chronic hepatitis C // World J. Gastroenterol.- 2011.- Vol. 17 (16).- P 2155-2158.; Стасишкис Т.А., Дунаева Н.В., Ковеленов А.В., Киселёв О.И. Динамика концентрации рибавирина в эритроцитах и плазме больных хроническим гепатитом С (ХГС) и её клиническое значение / Мат. XIX Российского конгресса «Гепатология сегодня» (Москва, 24-26 марта 2014 г) // Рос. журнал гастроэнтерологии, гепатологии, колопроктологии.- 2014.- Т. 24 (1), Приложение 43.- С. 33.; Стасишкис Т.А., Дунаева Н.В., Ковеленов А.В., Киселёв О.И. Динамика уровня гемоглобина и концентрации рибавирина в эритроцитах у HCV и HCV/ВИЧ-инфицированных, получающих противовирусную терапию / Мат. VI Ежегодного Всерос. конгресса по инфекционным болезням (Москва, 24-26 марта 2014 г.) // Инфекционные болезни.- 2014.- Т. 12, Прил. 1.- С. 298.; Schmid M., Kreil A., Jessner W., Homoncik M., Datz C., Gangl A., Ferenci P., Peck-Radosavljevic M. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens // Gut.- 2005.- Vol. 54 (7).- P 1014 - 1020.; Kobayashi T., Hige S., Terashita K., Nakai M., Horimoto H., Sho T., Nakanishi M., Ogawa K., Chuma M., Sakamoto N., Asaka M. Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C // J. Gastroenterol.- 2012.- Vol. 47 (11).- P 1228 - 1237.; Sullivan P.S., Hanson D.L., Brooks J.T. Impact on hemoglobin of starting combination antiretroviral therapy with or without zidovudine in anemic HIV-infected patients // J. Acquir Immune Defic. Syndr.- 2008.- Vol. 48 (2).- P 163-168.; Butt A.A., Umbleja T., Andersen J.W., Chung R.T., Sherman K.E. The incidence, predictors and management of anaemia and its association with virological response in HCV/HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin // Aliment. Pharmacol. Ther.- 2011.- Vol. 33(11).- P 1234 - 1244.; Breilh D., Djabarouti S., Trimoulet P., Le Bail B., Dupon M., Ragnaud J.M., Fleury H., Saux M.C., Thiébaut R., Chêne G., Neau D. Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients // J. Acquir. Immune Defic. Syndr.- 2009.- Vol. 52 (3).- P 428-430.; Morello J., Soriano V., Barreiro P., Medrano J., Madejón A., González-Pardo G., Jiménez-Nácher I., González-Lahoz J., Rodríguez-Novoa S. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C // Antimicrob. Agents Chemother.- 2010.- Vol. 54 (4).- P 1647 - 1649.; Wang Q., Miyakawa Y., Fox N., Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1 // Blood.- 2000.- Vol. 96 (6).- P 2093-2099.; Ducoulombier D., Roque-Afonso A-M., Di Liberto G., Penin F., Kara R., Richard Y., Dussaix E., Feray C. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes // Hepatology.- 2004.- Vol. 39 (3).- P 817-825.; de Almeida A.J., Campos-de-Magãlhaes M., de Melo Marçal O.P., Brandão-Mello C.E., Okawa M.Y., de Oliveira R.V., do Espirito-Santo M.P., Yoshida C.F., Lampe E. Hepatitis C virus-associated thrombocytopenia: a controlled prospective, virological study // Ann. Hematol.- 2004.- Vol. 83 (7).- P 434-440.; de Almeida A.J., Campos-de-Magalhaes M., Brandão-Mello C.E., de Oliveira R.V., Yoshida C.F., Lampe E. Detection of hepatitis C virus in platelets: evaluating its relationship to viral and host factors // Hepatogastroenterology.- 2007.- Vol. 54 (75).- P 964-968.; Padovani J.L., Corvino S.M., Drexler J.F., Silva G.F., Pardini M.I., Grotto R.M. In vitro detection of hepatitis C virus in platelets from uninfected individuals exposed to the virus // Rev. Soc. Bras. Med. Trop.- 2013.- Vol. 46 (2).- P 154-155.; Bordin G., Ballaré M., Zigrossi P., Bertoncelli M.C., Paccagnino L., Baroli A., Brambilla M., Monteverde A., Inglese E. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? // Clin. Exp. Rheumatol.- 1995.- Vol. 13 (Suppl. 13).- S 39-43.; Webster G.F. Local therapy for muculocutaneous Kaposi’s sarcoma in patients with acquired immunodeficiency syndrome // Dermatol. Surg.- 1995.- Vol. 21 (3).- P. 205-229.

Διαθεσιμότητα: https://hiv.bmoc-spb.ru/jour/article/view/81
https://doi.org/10.22328/2077-9828-2015-7-2-27-40

РОЛЬ ИНТЕРФЕРОНА-АЛЬФА В ИММУНОЛОГИЧЕСКОМ ОТВЕТЕ НА ФОНЕ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ХРОНИЧЕСКОГО ГЕПАТИТА С У ПАЦИЕНТОВ С ВГС/ВИЧ-КО-ИНФЕКЦИЕЙ

Συγγραφείς: ЛИ Ю.А, СКЛЯР Л.Ф., МАРКЕЛОВА Е.В., БОРИСЕНКО Е.А.

Θεματικοί όροι: ПЕГИЛИРОВАННЫЙ ИНТЕРФЕРОН,PEGYLATED INTERFERON,РИБАВИРИН,RIBAVIRIN,Т-ЛИМФОЦИТЫ CD4+,АНТИРЕТРОВИРУСНАЯ ТЕРАПИЯ,ANTIRETROVIRAL THERAPY,CD4+ T CELLS

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/rol-interferona-alfa-v-immunologicheskom-otvete-na-fone-protivovirusnoy-terapii-hronicheskogo-gepatita-s-u-patsientov-s-vgs-vich-ko
http://cyberleninka.ru/article_covers/16448723.png

DIFFERENT COURSES OF HBV INFECTION AFTER LIVER TRANSPLANTATION ; КЛИНИЧЕСКИЕ ВАРИАНТЫ ИНФЕКЦИИ HBV У БОЛЬНЫХ, ПЕРЕНЕСШИХ ТРАНСПЛАНТАЦИЮ ПЕЧЕНИ

Συγγραφείς: V. E. Syutkin, O. I. Andreytzeva, A. A. Salienko, A. O. Chugunov, A. V. Chzhao, В. Е. Сюткин, О. И. Андрейцева, А. А. Салиенко, А. О. Чугунов, А. В. Чжао

Πηγή: Russian Journal of Transplantology and Artificial Organs; Том 13, № 2 (2011); 37-45 ; Вестник трансплантологии и искусственных органов; Том 13, № 2 (2011); 37-45 ; 1995-1191 ; 10.15825/1995-1191-2011-2

Θεματικοί όροι: упреждающая терапия, pegylated interferon, HBV de novo, recurrent, preemptive therapy, пегилированный интерферон, инфекция HBV de novo, инфекция HBV возвратная

Περιγραφή αρχείου: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/372/312; Сюткин В.Е., Андрейцева О.И., Салиенко А.А. и др. Вакцинация против HBV больных, находящихся в листе ожидания трансплантации печени // Инфекци- онные болезни. 2010. Vol. 8 (4). P. 45–49.; Barcena R., Moraleda G., Moreno J. et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positi- ve livers // World J. Gastroenterol. 2006. Vol. 12 (13). P. 2070–2074.; Cahlin C., Olausson M., and Friman S. Severe clinical course of de novo hepatitis B infection after liver trans- plantation // Transplant Proc. 2001. Vol. 33 (4). P. 2467– 2468.; Castells L., Vargas V., Rodriguez F. et al. Clinical impact and efficacy of lamivudine therapy in de novo hepati- tis B infection after liver transplantation // Liver Transpl. 2002. Vol. 8 (10). P. 892–900.; Chazouilleres O., Mamish D., Kim M. et al. «Occult» hepatitis B virus as source of infection in liver transplant recipients // Lancet. 1994. Vol. 343 (8890). P. 142–146.; Crespo J., Fabrega E., Casafont F. et al. Severe clini- cal course of de novo hepatitis B infection after liver transplantation // Liver Transpl Surg. 1999. Vol. 5 (3). P. 175–183.; Demetris A.J., Todo S., Van Thiel D.H. et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations // Am. J. Pathol. 1990. Vol. 137 (3). P. 667–676.; Donataccio D., Roggen F., De Reyck C. et al. Use of an- ti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool // Transpl. Int. 2006. Vol. 19 (1). P. 38–43.; Douglas D.D., Rakela J., Taswell H. et al. Transmissi- on of hepatitis B virus infection from orthotopic donor livers [abstract] // Hepatology. 1992. Vol. 16 (Suppl). P. 49A.; Douglas D.D., Rakela J., Wright T.L. et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient // Liver Transpl. Surg. 1997. Vol. 3 (2). P. 105–111.; EASL Clinical Practice Guidelines: management of chro- nic hepatitis B // J. Hepatol. 2009. Vol. 50 (2). P. 227–242.; Fabia R., Levy M.F., Crippin J. et al. De novo hepatitis B infection after liver transplantation: source of disease, in- cidence, and impact // Liver Transpl. Surg. 1998. Vol. 4 (2). P. 119–127.; Jiang L., Jiang L.S., Cheng N.S. et al. Current prophylactic strategies against hepatitis B virus recurrence af- ter liver transplantation // World J. Gastroenterol. 2009. Vol. 15 (20). P. 2489–2499.; Jiang L. and Yan L.N. Current therapeutic strategies for recurrent hepatitis B virus infection after liver trans- plantation // World J. Gastroenterol. 2010. Vol. 16 (20). P. 2468–2475.; Kim K.K., Kim K.H., Hwang S. et al. Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report // Korean J. Gastroenterol. 2005. Vol. 45 (3). P. 174–180.; Marusawa H., Uemoto S., Hijikata M. et al. Latent hepatitis B virus infection in healthy individuals with an- tibodies to hepatitis B core antigen // Hepatology. 2000. Vol. 31 (2). P. 488–495.; Perrillo R., Rakela J., Dienstag J. et al. Multicenter stu- dy of lamivudine therapy for hepatitis B after liver trans- plantation. Lamivudine Transplant Group // Hepatology. 1999. Vol. 29 (5). P. 1581–1586.; Prieto M., Gomez M.D., Berenguer M. et al. De novo he- patitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population // Liver Transpl. 2001. Vol. 7 (1). P. 51–58.; Razonable R.R. Cytomegalovirus infection after liver transplantation: current concepts and challenges // World J. Gastroenterol. 2008. Vol. 14 (31). P. 4849– 4860.; Roche B., Samuel D., Gigou M. et al. De novo and appa- rent de novo hepatitis B virus infection after liver trans- plantation // J. Hepatol. 1997. Vol. 26 (3). P. 517–526.; Roque-Afonso A.M., Feray C., Samuel D. et al. Antibo- dies to hepatitis B surface antigen prevent viral reactiva- tion in recipients of liver grafts from anti-HBC positive donors // Gut. 2002. Vol. 50 (1). P. 95–99.; Segovia R., Sanchez-Fueyo A., Rimola A. et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation // Liver Transpl. 2001. Vol. 7 (2). P. 106–112.; Su W.J., Ho M.C., Ni Y.H. et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection // J. Pediatr. Gastroenterol Nutr. 2009. Vol. 48 (2). P. 203–208.; Takemura N., Sugawara Y., Tamura S. et al. Liver trans- plantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience // Dig Dis Sci. 2007. Vol. 52 (10). P. 2472–2477.; Toniutto P., Fumo E., Caldato M. et al. Favourable out- come of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation // Transplantation. 2004. Vol. 77 (3). P. 472–473.; Uemoto S., Sugiyama K., Marusawa H. et al. Transmis- sion of hepatitis B virus from hepatitis B core antibo- dy-positive donors in living related liver transplants // Transplantation. 1998. Vol. 65 (4). P. 494–499.; Umeda M., Marusawa H., Ueda M. et al. Beneficial ef- fects of short-term lamivudine treatment for de novo he- patitis B virus reactivation after liver transplantation // Am. J. Transplant. 2006. Vol. 6 (11). P. 2680–2685.; Wachs M.E., Amend W.J., Ascher N.L. et al. The risk of transmission of hepatitis B from HBsAg(–), HBcAb(+), HBIgM(–) organ donors // Transplantation. 1995. Vol. 59 (2). P. 230–234.; Yilmaz N., Shiffman M.L., Todd Stravitz R. et al. Prophy- laxis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 ye- ars // Liver Int. 2008. Vol. 28 (1). P. 72–78.; https://journal.transpl.ru/vtio/article/view/372

Διαθεσιμότητα: https://journal.transpl.ru/vtio/article/view/372
https://doi.org/10.15825/1995-1191-2011-2-37-45

The expirience of IDEAL ; УРОКИ ИССЛЕДОВАНИЯ IDEAL

Συγγραφείς: E. Z. Burnevich, Э. З. Бурневич

Πηγή: Journal Infectology; Том 2, № 1 (2010); 66-74 ; Журнал инфектологии; Том 2, № 1 (2010); 66-74 ; 2072-6732 ; 10.22625/2072-6732-2010-2-1

Θεματικοί όροι: рибавирин, treatment, pegylated interferon-α, ribavirin, лечение, пегилированный интерферон-α

Περιγραφή αρχείου: application/pdf

Relation: https://journal.niidi.ru/jofin/article/view/287/284; National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology. – 2002. 36(Suppl. 1). – S3–S20.; Strader, D.B. Diagnosis, management, and treatment of hepatitis C / D.B. Strader [et al] // Hepatology. – 2004. – 39. – P. 1147–1171.; Dienstag, J.L. American Gastroenterological Association technical review on the management of hepatitis C /J.L. Dienstag, J.G. McHutchison // Gastroenterology. – 2006. – 130. –P. 231–264.; Приказ министерства здравоохранения и социального развития Российской Федерации от 23 ноября 2004 г. № 260 «Об утверждении стандарта медицинской помощи больным хроническим гепатитом В, хроническим гепатитом С».; Manns, M.P. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial / M.P. Manns [et al.] // Lancet. – 2001. – 358 (9286). – P. 958–965.; Fried, M.W. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection / M.W. Fried [et al.] //N. Engl. J. Med. – 2002. – 347 (13). – P. 975–982.; Lindsay, K.L. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C / K.L. Lindsay [et al.] // Hepatology. – 2001. – 34. P. 395–403.; http://www.fda.gov/cder/foi/appletter/2001/pegsche 080701L.htm; Jacobson, I.M. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial / I.M. Jacobson [et al.] // Hepatology. – 2007. – 46. – Р. 971–981.; Sulkowski, M.S. Final results of the IDEAL (Individualzed Dosing Efficacy versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy) phase IIIb study / M.S. Sulkowski [et al.] // J. Hepatol. – 2008. – 48 (Supl. 2). – A. 991.; McHutchison, J.G. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. /J.G. McHutchison [et al.] // N. Engl. J. Med. – 2009. – 361. – Р. 580–593.; McCone, J. Sustained virologic response and predictors of response in african american patients in the IDEAL (Individualized Dosing Efficacy Versus Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) phase 3b study /J. McCone [et al.] // Hepatology. – 2008. – 48 (Suppl.). – A. 268.; Nyberg, L.M. Predicting the ability to achieve a sustained virologic response in the first 12 weeks: results from the IDEAL study / L.M. Nyberg [et al.] // Hepatology. – 2008. – 48 (Suppl.). – A. 1850.; Sulkowski, M. Probability of sustained virologic response is associated with the magnitude of HCV RNA reduction at week 4 of treatment with peginterferon plus ribavirin: results of the IDEAL trial / M. Sulkowski [et al.] // Hepatology. – 2008. – 48 (Suppl.). – A. 1868.; Sulkowski, M. Treatment-related anemia but not epoetin use is associated with higher SVR rates among persons treated ith peginterferon/ribavirin: results from the IDEAL study /M. Sulkowski [et al.] // Hepatology. – 2008. – 48 (Suppl.). –A. 1851.; Reddy, K.R. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirint Treatment / K.R. Reddy [et al.] // Clin. Gastroenterol. Hepatol. – 2007. – 5. – 124–129.; McHutchison, J.G. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C / J.G. McHutchison [et al.] //Gastroenterology. – 2002. – 123. – Р. 1061–1069.; http://www.hivandhepatitis.com/hep_c/news/2007/082207_ideal.html; http://www.roche.ru/content/ru/section-2006-03-28-22-09-12/publication-2008-01-31-10-00-55.html; Сюткин, В.Е. Так ли идеален «IDEAL»? / В.Е. Сюткин //Инфекционные болезни. – 2008. – 2. – Р. 100–103.; Jensen, D.M. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a/ribavirin therapy / D.M. Jensen [et al.] // Hepatology. – 2006. – 43. – Р. 954–960.; Zeuzem, S. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia / S. Zeuzem [et al.] // J.Hepatol. – 2006. – 44. – Р. 97–103.; https://journal.niidi.ru/jofin/article/view/287

Διαθεσιμότητα: https://journal.niidi.ru/jofin/article/view/287
https://doi.org/10.22625/2072-6732-2010-2-1-66-74

Iron metabolism in chronic hepatitis C patients on antiviral treatment ; Метаболизм железа у больных хроническим вирусным гепатитом С на фоне противовирусного лечения

Συγγραφείς: K. V. Zhdanov, D. A. Gusev, V. S. Chirskiy, K. V. Kozlov, К. В. Жданов, Д. А. Гусев, В. С. Чирский, К. В. Козлов

Πηγή: Journal Infectology; Том 1, № 1 (2009); 41-48 ; Журнал инфектологии; Том 1, № 1 (2009); 41-48 ; 2072-6732 ; 10.22625/2072-6732-2009-1-1

Θεματικοί όροι: рибавирин, iron metabolism antiviral treatment, peg-interferon, ribavirin, метаболизм железа, противовирусная терапия, пегилированный интерферон

Περιγραφή αρχείου: application/pdf

Relation: https://journal.niidi.ru/jofin/article/view/327/324; Гусев Д.А. Хронический гепатит С: течение, прогноз и лечение больных в военно-медицинских учреждениях: Автореф. дис. . д-ра. мед. наук / Д.А. Гусев. – СПб., 2006. – 46 с.; Жданов К.В. Латентные формы вирусных гепатитов В и С у лиц молодого возраста: Автореф. дис. … д-ра мед. наук / К.В. Жданов. – СПб., 2000. – 44 c.; Жданов К.В. Характеристика метаболизма железа у больных хроническим гепатитом С / К.В. Жданов, Д.А. Гусев, В.С. Чирский и др. // Клинические перспективы гастроэнтерологии, гепатологии. – 2009. - №1., – С. 10-17.; Кулагина Е.А. Синдром перегрузки железом при хроническом вирусном гепатите С: автореф. дис. … канд. мед. наук / Е.А.Кулагина. – Новосибирск, 2001. – 21 с.; Маммаев С.Н. Показатели метаболизма железа и антиоксидантная активность сыворотки крови у больных хроническим вирусным гепатитом С / С.Н. Мамаев, Е.А. Лукина, Ч.С. Павлов, А.А и др. // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. – 2003. – T. 13, №2. – C. 32-37.; Deugenier Y. Iron and HCV: the middle age / Y. Deugenier, D. Guyader // Manuscripts of 2nd International Conference on the Management of Patient with Viral Hepatitis. – Paris., 2007. – P. 131-137.; Никитин И.Г. Уровень сывороточного железа и результаты интерферонотерапии у больных хроническим гепатитом С / И.Г. Никитин, С.Л. Кузнецов, Г.И. Сторожаков // Российский журнал гастроэнтерологии, гепатологии, колопроктологии.- 2000.- Т.10, №3.- С. 32-35.; Kageyama F. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C / F. Kageyama // Am. J. Gastroenterol. – 2000. – Vol. 95, № 4. – P. 1041-1050.; Kakizaki S. Histological change after interferon therapy in chronic hepatitis C in view of iron deposition in the liver / S. Kakizaki, H. Takagi, T. Ichikawa et al. // Biol. Trace Elem. Res. – 2000. – Vol. 73, № 2. – P. 151-162; Arber N. Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection / N. Arber, M. Moshkowitz, F. Konikoff et al. // Dig. Dis. Sci. – 1995. – Vol. 40, № 11. – P. 2431-2433.; Pianko S. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection / S. Pianko, J.G. McHutchison, S.C. Gordon et al. // J. Interferon Cytokine Res.– 2002. – Vol. 22, 4. – P. 483-489.; Souza R.M. Effect of iron overload on the severity of liver histologic on the response to interferon and ribavirin therapy of patients with hepatitis C infection / R.M. Souza, L.A. Freitas, A.C. Lira et al. // Braz. Med. Biol. Res. – 2006. – Vol. 39, № 1. – P. 79-83.; Shedlofsky S.I. Role of iron in the natural history and clinical course of hepatitis C disease / S.I. Shedlofsky // Hepatogastroenterology. – 1998. – Vol. 45, 20. – P. 349-355.; Fillebeen C. Expression of the subgenomic hepatitis C virus replicon alters iron homeostasisin Huh7 cells / C. Fillebeen, M. Muckenthaler, B. Andriopoulos et al. // Hepatol. – 2007. - Vol. 47, 1. – P. 12-22.; Fillebeen C. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C virus / Fillebeen C., A. Rivas-Estilla, M. Bisaillon // The Journal of biological chemistry. – 2005. – Vol.280, №10. – P. 9049-9057.; Лобзин Ю.В. Вирусные гепатиты / Ю.В. Лобзин, К.В. Жданов, В.М. Волжанин, Д.А. Гусев. – СПб.: ИКФ «Фолиант», 2006. – 192 с.; https://journal.niidi.ru/jofin/article/view/327

Διαθεσιμότητα: https://journal.niidi.ru/jofin/article/view/327
https://doi.org/10.22625/2072-6732-2009-1-1-41-48

Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C ; Ранний вирусологический ответ при использовании препарата цепэгинтерферона альфа-2b в комбинации с рибавирином в терапии хронического гепатита С

Συγγραφείς: O. O. Znoyko, M. V. Maevskaya, E. A. Klimova, S. L. Maksimov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, R. A. Ivanov, Yu. N. Linkova, T. V. Chernovskaya, О. О. Знойко, М. В. Маевская, Е. А. Климова, С. Л. Максимов, С. Н. Кижло, Н. А. Петроченкова, Ф. И. Нагимова, Р. А. Иванов, Ю. Н. Линькова, Т. В. Черновская

Πηγή: Journal Infectology; Том 5, № 1 (2013); 83-90 ; Журнал инфектологии; Том 5, № 1 (2013); 83-90 ; 2072-6732 ; 10.22625/2072-6732-2013-5-1

Θεματικοί όροι: Альгерон, treatment, early virologic response, pegylated interferon alfa, cepeginterferon alfa-2b, Algeron, лечение, ранний вирусологический ответ, пегилированный интерферон альфа, цепэгинтерферон альфа 2b

Περιγραφή αρχείου: application/pdf

Relation: https://journal.niidi.ru/jofin/article/view/158/153; Lavanchy, D. The global burdgen of hepatitis C / D. Lavanchy // Liver Int. – 2009. – № 29 (suppl 1). – Р. 74–81.; Sheppard, C.W. Global epidemiology of hepatitis C virus infection / C.W. Sheppard, L. Finelli, M.J. Alter // Lancet Infect. Dis. 2005. – № 5. – Р. 558–567.; Ющук, Н.Д. Протокол диагностики и лечения больных вирусными гепатитами В и С / Н.Д. Ющук [и др.] // РЖГГК. – 2010. – № 6. – С. 5–60.; Reddy, K.R. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C / K.R. Reddy [et al.] // Hepatology. – 2001. – № 33 (2). – Р. 433–438.; Кузин, С.Н. Распространение гепатита С и отдельных генотипов вируса гепатита С в регионе с умеренной активностью эпидемического процесса / С.Н. Кузин [и др.] // Вопросы вирусологии. – 1999. – № 2. – С. 79–82.; Shustov, A. The prevalence, subtype distribution and molecular variability of hepatitis С virus (HCV) in the territory of Western Siberia / A. Shustov [et al.] // Xlth Intern. Congress of Virology. Sydney, Australia. – 1999. – Р. 279.; Быстрова, Т.Н. Характеристика репликативной формы хронического гепатита С / Т.Н. Быстрова, М.К. Абрамова, Ю.В. Михайлова // Инфекция и иммунитет. – 2012. – Т. 2, № 1–2. – С. 436.; Ge, D. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance / D. Ge [et al.] // Nature. – 2009. – № 461. – Р. 798–401.; Statermayer, A.F. Impact of IL28B genotype on the early and sustained virologic response in the treatment-naïve patients with chronic hepatitis C / A.F. Statermayer [et al.] // Clin. Gastroenterol. Hepatol. – 2011. – №9. – Р. 344–350.; Lee, S.S. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD) / S.S. Lee [et al.] // J. Hepatol. – 2002. – № 37 (4). – Р. 500–506.; Marcellin, P. Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) / P. Marcellin [et al.] // 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA November 2–6, 2007.; Богословская, Е.В. Оценка эффективности противовирусной терапии хронического гепатита С в максимально ранние сроки / Е.В. Богословская [и др.] // РЖГГК. – 2007. – № 2. – С. 36–39.; https://journal.niidi.ru/jofin/article/view/158

Διαθεσιμότητα: https://journal.niidi.ru/jofin/article/view/158
https://doi.org/10.22625/2072-6732-2013-5-1-83-90

Evolution of antiviral treatment chronic for hepatitis B, C and D ; ЭВОЛЮЦИЯ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ХРОНИЧЕСКИХ ГЕПАТИТОВ В, С И D

Συγγραφείς: K. V. Zhdanov, K. V. Kozlov, V. S. Sukachev, К. В. Жданов, К. В. Козлов, В. С. Сукачев

Πηγή: Journal Infectology; Том 1, № 4 (2009); 23-35 ; Журнал инфектологии; Том 1, № 4 (2009); 23-35 ; 2072-6732 ; 10.22625/2072-6732-2009-1-4

Θεματικοί όροι: аналоги нуклеоз(т)идов, Interferon, Peginterferon, Nucleos(t)ide analogues, интерферон, пегилированный интерферон

Περιγραφή αρχείου: application/pdf

Relation: https://journal.niidi.ru/jofin/article/view/270/267; Sherlock S. Course of long incubation (virus B) hepatitis / S. Sherlock // Brit. Med. Bull. 1972. – Vol.28. –P. 109–113.; Levene C. Incidence of antibodies against betalipoproteins (Ag system), and the factors influencing isoimmunisation in transfused patients in the U.S.A. and Italy / C. Levene, B.S. Blumberg, A. Vierrucci et al. // Lancet. – 1967. – Vol.2, №7516. – P. 582–585.; Dane D.S. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis / D.S. Dane, C.H. Cameron, M. Briggs // Lancet. – 1970. – Vol.1, №7649. – P. 695–698.; Vilela M.D. Action of an anti-viral on the Australia antigen in patients with hepatitis A virus and in healthy carriers /M.D. Vilela, W.A. Siqueira, L.D. Rodriguez et al. // G E N. – 1977. – Vol. 31, №3. –P. 149–155.; Whitley R. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use / R. Whitley, C. Alford, F. Hess et al. // Drugs. – 1980. – Vol. 20, №4. – P. 267–282.; Auer I.O. Therapy of chronic hepatitis (author’s transl) / I.O. Auer // Leber Magen Darm. – 1980. – Vol.10, №5. – P. 251–258.; Sherlock S. Treatment of chronic hepatitis /S. Sherlock // Ann Acad Med Singapore. – 1980 – Vol.9, №2. – P. 185–187.; Hafkin B. Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses / B. Hafkin, R.B. Pollard, M.L. Tiku et al. // Antimicrob Agents Chemother – 1979. – Vol.16, №6. – P. 781–787.; Fattovich G. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B /G. Fattovich, L. Brollo, S. Boscarro et al. // J.Hepatol. – 1989. – Vol.9, №3. – P. 331–337.; Coppens J.P. Prospective trial of recombinant leucocyte interferon in chronic hepatitis B: a 10-month follow up study / J.P. Coppens, C. Cornu, E. Lens et al. // Liver. – 1989. – Vol.9, №5. – P. 307–313.; Porres J.C. Different doses of recombinant alpha interferon in the treatment of chronic hepatitis B patients without antibodies against the human immunodeficiency virus / J.C. Porres, V. Carreo, I. Mora et al. // Hepatogastroenterology. – 1988. – Vol.35, №6. – P. 300–303.; Brook M.G. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection / M.G. Brook, L. Petrovic, J.A. McDonald et al. // J. Hepatol. – 1989. – Vol.8, №2. – P. 218–225.; Marcellin P. Vidarabine treatment of chronic active hepatitis associated with hepatitis B virus multiplication. A randomized multicenter study / P. Marcellin, D. Ouzan, F. Degos et al. // Gastroenterol Clin. Biol. – 1987. – Vol.11, №8-9. – P. 568–573.; Di Bisciglie A.M. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B /A.M. Di Bisciglie, T.L. Fong, M.W. Fried et al. // Am J Gastroenterol. – 1993. – Vol.88, №11. – P. 1887–1892.; Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. / F. Tin, A. Liberati, A. Crax et al. // J Hepatol. 1993 Jun;18(2):154–62.; Lok A.S. Treatment of chronic hepatitis B / A.S. Lok //J. Viral. Hepat. – 1994. – Vol.1, №2. – P. 105–124.; Dusheiko G.M. Lamivudine treatment of chronic hepatitis B / G.M. Dusheiko // Rev. Med. Virol. – 1998. –Vol.8 – P. 153–159.; Hong J.H. Current status of anti-HBV chemotherapy /J.H. Hong, Y. Choi, B.K. Chun et al. // Arch Pharm. Res. –1998. – Vol.21, №2. – P. 89–105.; Doong S.L. Inhibition of the replication of hepatitis B virus in vitro by 2’,3’-dideoxy-3’-thiacytidine and related analogues / S.L. Doong, C.H. Tsai, R.F. Schinazi et al. // Proc. Natl. Acad. Sci. U S A. – 1991. – Vol.88, №19. – P. 8495–8499.; Lai C.L. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group / C.L. Lai, R.N. Chien, N.W. Leung et al. // N. Engl. J. Med. – 1998. – Vol.339. – P. 61–68.; Sokal E. Doze finding and safety of lamivudine in children and adolescents with chronic hepatitis B / E. Sokal, E.A. Roberts, G. Mieli-Vergani et al. // Hepatology. – 1998. – Vol.28. – P. 489A.; Grellier L. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis / L. Grellier,D. Mutimer, M. Ahmend et al. // Lancet. - 1996. – Vol.348. – P. 1212–1215.; Perrilo R. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation / R. Perrilo, J. Rakela, J. Deinstage et al. // Hepatology. – 1999. – Vol.29. – P. 1581–1586.; Hadziyannis S.J. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years / S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote et al. // Gastroenterology. – 2006. – Vol.131, №6. – P. 1743–1751.; Melegari M. Hepatitis B mutants associated with 3 TC and famciclovir administration are replication defective /M. Melegari, P.P. Scaglioni, J.R. Wands // Hepalology. – 1998. – Vol.27. – P. 628–633.; Hadziyannis S.J. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B / S.J. Hadziyannis, G.V. Papatheodoridis, E. Dimou et al. // Hepatology. – 2000. – Vol.32, №4, Pt.1. – P. 847–851.; Lin S.M. Interferon therapyin HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma / S.M. Lin, M.L. Yu, C.M. Lee et al. // J. Hepatol. – 2007. – Vol.46, №1. – P. 45–52.; Lampertico P. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy / P. Lampertico, E. Del Ninno, M. Vigan et al. // Hepatology. – 2003. – Vol.37, №4. – P. 756–763.; Moucari R. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up / R. Moucari, A. Korevaar, O. Lada et al. // J. Hepatol. – 2009. – Vol.50, №6. – P. 1084– 1092.; Fattovich G. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) / G. Fattovich, G. Giustina, J. Sanchez- Tapias et al. // Am J. Gastroenterol. – 1998. – Vol.93, №6. – P. 896–900.; Lau G.K. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B / G.K. Lau, T. Piratvisuth, K.X. Luo et al. // N. Engl. J. Med. – 2005. – Vol.352, №26. – P. 2682–2695.; Janssen H.L. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial / H.L. Janssen, M. van Zonneveld, H. Senturk et al. // Lancet. – 2005. – Vol.365, №9454. – P. 123–129.; Chan H.L. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone / H.L. Chan, N.W. Leung, A.Y. Hui et al. // Ann Intern Med. – 2005. – Vol.142, №4. – P. 240–250.; Marcellin P. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B / P. Marcellin, G.K. Lau, F. Bonino et al. // N. Engl. J. Med. – 2004. – Sep.; Buster E.H. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b / E.H. Buster, H.J. Flink, Y. Cakaloglu et al. // Gastroenterology. – 2008. – Vol.135, №2. – P. 459–467.; Marcellin P. Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a / P. Marcellin, F. Bonino, G.K. Lau et al. // Gastroenterology. – 2009. – Vol.136, №7. – P. 2169– 2179. – e.1–4.; Buster E.H. Factors that Predict Response of Patients with Hepatitis Be Antigen-Positive Chronic Hepatitis B to Peginterferon-alpha / E.H. Buster, B.E. Hansen, G.K. Lau et al. // Gastroenterology. – 2009. – Sep. 5. В печати.; Нурмухаметова Е.А. Генотипы вируса гепатита В: потенциальное клиническое значение / Е.А. Нурмухаметова, Н.П. Блохина // Фарматека. – 2008. – Т.156, №2. – С.33–35.; EASL Clinical Practice Guidelines: managment of chronic hepatitis B. European Association For The Study Of The Liver // J. Hepatol. – 2009. – Vol. 50, №2. – P. 227–242.; Brunetto M.R. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAgnegative chronic hepatitis B / M.R. Brunetto, F. Moriconi, F. Bonino et al. // J. Gepatol. – 2009. – Vol.49, №4. – P. 1141–1150.; Moucari R. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa- 2a in HBeAg-negative patients / R. Moucari, V. Mackiewicz, O. Lada et al. // Hepatology. – 2009. – Vol.49, №4. – P. 1151–1157. PEGASYS and its association with post-treatment response in HBeAg positive chronic hepatitis B.; GKK Lau // Presented at: Asian Pacific Association for the Study of the Liver (APASL). –Poster 083. – February 13–16, 2009; Hong Kong, China.; Chang T.T. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B; BEHoLD; AI463022 Study Group / T.T. Chang, R.G. Gish, R. de Man et al. // N. Engl. J. Med. – 2006. – Vol.354, №10. – P. 1001– 1010.; Lai C.L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B; BEHoLD AI463027 Study Group / C.L. Lai, D. Shouval, A.S. Lok et al. // N. Engl. J. Med. – 2006. – Vol. 354, №10. – P. 1011–1020.; Gish R.G. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B / R.G. Gish //Gastroenterology. – 2007. – Vol.133. – P. 1437–1444.; Lai C.L. Telbivudine versus lamivudine in patients with chronic hepatitis B / C.L. Lai, E. Gane, Y.F. Liaw et al. // N. Engl. J. Med. – 2007. – Vol.357. – P. 2576–88.; Liaw Y.F. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B; GLOBE Study Group / Y.F. Liaw, E. Gane, N. Leung et al. // J. Gastroenterol. – 2009. – Vol.136, №2. – P. 486–495.; Zeuzem S. Baseline characteristics and early ontreatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B / S. Zeuzem, E. Gane, Y.F. Liaw et al. // J. Hepatol. – 2009. – Vol.51, №1. – P. 11–20.; Keeffe E.B. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update / E.B. Keeffe, D.T. Dieterich, S.H. Han et al. // Clin. Gastroenterol. Hepatol. – 2008. – Vol.6, №12. – P. 1315– 1341.; Marcellin P. Tenofovir dixoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B / P. Marcellin, E.J. Heathcote, M. Buti et al. // N. Engl. J. Med. – 2008. – Vol.359, №23. – P. 2442–2455.; Rajendra A. Economics of chronic hepatitis B and hepatitis C / A. Rajendra, J.B. Wong // J . Hepatol. – 2007. –Vol.47, №4. – P. 608–617.; Takkenberg B. Baseline HBsAg level predict HBsAg loss in chronic hepatitis B patients treated with a combination of peginterferon alfa-2a and adefovir: an interim analysi / B. Takkenberg, H. Zaaijer, C. Weegink et al. // J. Hepatol. – 2009. – Vol 50 (Suppl 1) . – P. S8.; Rizzetto M. Treatment of chronic delta hepatitis with alpha-2 recombinant interferon / M. Rizzetto, F. Rosina, G. Saracco et al. // J. Hepatol. – 1986. – Vol.3. – Suppl.2. – P. 229–233.; Rosina F. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study / F. Rosina, C. Pintus, C. Meschievitz et al. // Hepatology. – 1991. – Vol.13, №6. – P. 1052–1056.; Farci P. Treatment of chronic hepatitis D with interferon alfa-2a / P. Farci, A. Mandas, A. Coiana et al. //N.Engl.J.Med.– 1994. – Vol.330, №2. – P. 88–94.; Gaudin G.L. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial / G.L. Gaudin, P. Faure, H. Godinot et al. // Liver – 1995. – Vol.15, №1. – P. 45–52.; Castelnau C. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up / C. Castelnau, F. Le Gal, M.P. Ripault et al. // J. Hepatol. – 2006. – Vol.44, №3. – P. 728–735.; Niro G.A. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta / G.A. Niro, A. Ciancio, G.B. Gaeta et al. //Hepatology. – 2006. – Vol.44, №3. – P. 713–720.; Heidrich B. Virological and clinical characteristics of delta hepatitis in Central Europe / B. Heidrich, K. Deterding, H.L.Tillmann et al. // J. Viral Hepat. – 2009. – № 12. – P. 883–94.; Yurdaydin C. Hepatitis D. / C. Yurdaydin, E.S. Koytak, J.S. Glenn // Curr Treat Options Gastroenterol. – 2007. – Vol.10, №6. – P. 456–463.; Балаян М.С. Вирусные гепатиты. Энциклопедический словарь. – 2-е изд. / М. С. Балаян, М. И. Михайлов. – М., 1999. – 42 с.; Weisberg I. New Treatments for Hepatitis C: Life Cycle Lessions / I. Weisberg, S.H. Sigal, I.M. Jacobson //Current Hepatitis Reports. – 2007. – Vol.6. – P. 75–82.; Marcellin P. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects / P. Marcellin, M.A. Loriot, N. Boyer et al. // Hepatology. – 1990. – Vol.12, №1. – P. 155–158.; Tripi S. Interferon-alpha alone versus Interferonalpha plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-alpha Treatment / S. Tripi, G. Di Gaetano, M. Soresi et al. // BioDrugs. – 2000. – Vol.13, №4. – P. 299–304.; Barbaro G. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study / G. Barbaro, G. Di Lorenzo, M. Soldini et al. // Am J. Gastroenterol. – 1998. – Vol.93, №12. – P. 2445–2451.; Clarysse C. Genotype, serum level of HCV-RNA and response to interferon-alpha treatment in patients with chronic hepatitis C / C. Clarysse, C. Van den Eynde, F. Nevens et al. // Neth. J. Med. – 1995. – Vol.47, №6. – P. 265–271.; Lee S.S. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values/ S.S. Lee, M. Sherman // J Viral Hepat. – 2001. – Vol. 8, №3. – Р. 202–205.; Saracco G. The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review / G. Saracco, M. Rizzetto // J. Gastroenterol., Hepatol. – 1995. – Vol.10, №6. – P. 668–673.; Manns M.P. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial / M.P. Manns, J.G. McHutchison, S.C. Gordon et al. // Lancet. – 2001. – Vol.358, №9286. – P. 958–965.; Hadziyannis S.J. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose; PEGASYS International Study Group / S.J. Hadziyannis, H. Jr. Sette, T.R. Morgan et al. // Ann Intern Med. – 2004. – Vol.140, №5. – P. 346–355.; Лобзин Ю.В. Вирусные гепатиты: клиника, диагностика, лечение / Ю.В. Лобзин, К.В. Жданов, В.М. Волжанин, Д.А. Гусев. – Санкт-Петербург: Фолиант. – 2006. – 184 с.; Marcellin P. Improved Prediction of SVR by Differentiating Early Virologic Response (EVR) into Rapid Virologic Response (RVR), Complete EVR (cEVR) and Partial EVR (pEVR) in Genotype 1 Patients Treated ith Peginterferon Alfa- 2a (40KD) Pegasys ) and Ribavirin (Copegus ) / P. Marcellin, D. Jensen, S. J. Hadziyannis et al. // Hepatology International. – Vol.2, Supplement 3, №3 – 2008. – Abstract FP022. – P. 332.; Jensen D.M. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy / D.M. Jensen, T.R. Morgan , P. Marcellin et al. // J. Hepatol. – 2006. – Vol.43, №5. – P. 954–60.; Zeuzem S. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia / S .Zeuzem, M. Buti, P. Ferenci et al. // J. Hepatol. – 2006. – Vol.44, №1. – P. 97–103.; Fried M.W. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection / M.W. Fried, M.L. hiffman, K.R. Reddy et al. // N. Engl. J. Med.– 2002. – Vol.347, №13. – P. 975–982.; Ferenci P. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin / P. Ferenci, M.W. Fried, M.L. Shiffman et al. // J. Hepatol. – 2005. – Vol.43, №3. – P. 425–433.; Berg T. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferonalfa-2a plus ribavirin / T. Berg, M. von Wagner, S. Nasser et al. // J. Gastroenterol. – 2006. – Vol.130, №4. – P. 1086–1097.; Sanchez – Tapias J.M. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment / J.M. Sanchez – Tapias, M. Diago, P. Escartín, J. Enríquez et al. //J. Gastroenterol. – 2006. – Vol.130, №4. – 1086–1097.; Bronowicki J.P. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin / J.P. Bronowicki, D. Ouzan, T.Asselah et al. // J. Gastroenterol. – 2006. – Vol.131, №4. – P. 1040- 1048.; Pearlman B.L. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders / B.L. Pearlman, C. Ehleben, S. Saifee // J. Hepatol. – 2007. – Vol.46, №6. – 1688–1694.; Fried M.W., Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection / M.W. Fried // Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. – J. Hepatol. – April 2008.; Dalgard O. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response / O. Dalgard, K. Bjøro, H. Ring-Larsen et al. // J. Hepatol. – 2008. – Vol.47, №1. – P. 35–42.; Shiffman M.L. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3; ACCELERATE Investigators / M.L. Shiffman, F. Suter, B.R. Bacon et al. // N. Engl. J. Med. – 2007. – Vol.357, №2. – P. 124–134.; Willems B. 48 Weeks & High Ribavirin Dose May Improve SVR Rates for Genotype 2/3, French study / B. Willems // Program and abstracts of the 42nd Meeting of the EuropeanAssociation for the Study of Liver Diseases. – J. Hepatol. – April 2007.; Fried M.W. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin / M.W. Fried, D.M. Jensen, M. Rodriguez-Torres et al. // J. Hepatol. – 2008. – Vol.48, №4. – P.1033–1043.; Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM1) (SPRINT-2). In print // www.clinicaltrials. gov/ct2/show/NCT00705432?term=SPRINT-2&rank=1.; Zeuzem S. Telaprevir in combination with peginterferon –alfa-2а with or without ribavirin in the treatment of chronic hepatitis C: final results of the prove2 / S. Zeuzem, C. Hezode, P. Ferenci et al. // Abstract 243. – J. Hepatol. – 2008. – Vol.48, №4 (suppl). – P. 113 A.; Gane E.G. Antiviral activity of the HCV nucleocide polymerase inhibitor R7128 in HCV genotype 2 and 3 prior nonresponders: interim results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days / E.G. Gane, M. Rodriguez-Torres, D.R. Nelson et al. // J. Hepatol., Abstract LB10. – 2008. – Vol.48, №4 (suppl). – P. 267 A.; Maylin S. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C / S. Maylin, M. Martinot-Peignoux, R. Moucari et al. // J. Gastroenterol. – 2008. – Vol.135, №3. – P. 821–829.; https://journal.niidi.ru/jofin/article/view/270

Διαθεσιμότητα: https://journal.niidi.ru/jofin/article/view/270
https://doi.org/10.22625/2072-6732-2009-1-4-23-35

НЕКОТОРЫЕ АСПЕКТЫ БЕЗОПАСНОСТИ НОВОГО ОТЕЧЕСТВЕННОГО ПРЕПАРАТА ПЕГИЛИРОВАННОГО ИНТЕРФЕРОНА АЛЬФА «АЛЬГЕРОН» (РЕЗУЛЬТАТЫ КЛИНИЧЕСКОГО ИССЛЕДОВАНИЯ I ФАЗЫ)

Συγγραφείς: Тукач, Артем, Фитилев, Сергей, Шкребнева, Ирина, Возжаев, Александр, Якушев, Вадим, Иванов, Роман, Линькова, Юлия, Черновская, Татьяна

Θεματικοί όροι: ПЕГИЛИРОВАННЫЙ ИНТЕРФЕРОН АЛЬФА, ЦЕПЭГИНТЕРФЕРОН АЛЬФА-2B, ПЕРЕНОСИМОСТЬ, ПОБОЧНЫЕ РЕАКЦИИ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/nekotorye-aspekty-bezopasnosti-novogo-otechestvennogo-preparata-pegilirovannogo-interferona-alfa-algeron-rezultaty-klinicheskogo
http://cyberleninka.ru/article_covers/15663960.png

ЛЕЧЕНИЕ ХРОНИЧЕСКИХ ВИРУСНЫХ ГЕПАТИТОВ: ДОСТИЖЕНИЯ И ПЕРСПЕКТИВЫ

Συγγραφείς: Голованова, Е.

Θεματικοί όροι: ХРОНИЧЕСКАЯ HCV-ИНФЕКЦИЯ, ХРОНИЧЕСКАЯ HBV-ИНФЕКЦИЯ, ПРОТИВОВИРУСНАЯ ТЕРАПИЯ, ПЕГИЛИРОВАННЫЙ ИНТЕРФЕРОН, АНАЛОГИ НУКЛЕОЗИДОВ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/lechenie-hronicheskih-virusnyh-gepatitov-dostizheniya-i-perspektivy
http://cyberleninka.ru/article_covers/15742314.png